Table 2 Characteristics of patients in study population, by chemotherapy agenta
From: Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
All Agents | Carboplatin | Cisplatin | Cyclophosphamide | Fluorouracil | Gemcitabine | Oxaliplatin | Vincristine | |
|---|---|---|---|---|---|---|---|---|
(n = 215,508) | (n = 60,966) | (n = 22,393) | (n = 83,665) | (n = 42,970) | (n = 6617) | (n = 33,822) | (n = 14,610) | |
Patient | ||||||||
Age (years), mean (SD) | 57.3 (11.3) | 59.7 (11.3) | 57.6 (10.8) | 54.7 (10.9) | 58.1 (10.8) | 63.3 (11.4) | 57.6 (10.7) | 59.1 (14.0) |
Female, % | 69.5 | 72.8 | 40.1 | 89.0 | 46.9 | 51.2 | 42.5 | 42.5 |
Chronic Comorbidities, % | ||||||||
Cardiovascular Disease | 16.4 | 21.4 | 21.4 | 9.6 | 18.5 | 28.4 | 19.1 | 20.7 |
Cardiac Dysrhythmias | 8.1 | 10.0 | 9.8 | 5.0 | 9.7 | 14.3 | 10.3 | 10.4 |
Cerebrovascular Disease | 3.0 | 4.8 | 4.2 | 1.5 | 2.5 | 5.1 | 2.4 | 3.5 |
Ischemic Heart Disease | 8.4 | 11.3 | 11.9 | 4.3 | 9.7 | 15.9 | 9.7 | 10.7 |
Heart Failure | 2.6 | 3.7 | 2.6 | 1.4 | 2.9 | 5.2 | 2.9 | 3.7 |
Diabetes | 14.7 | 15.8 | 14.0 | 11.7 | 18.0 | 25.7 | 18.2 | 16.5 |
Liver Disease | 7.7 | 7.0 | 6.8 | 3.7 | 14.4 | 19.1 | 16.7 | 6.0 |
Lung Disease | 15.5 | 23.9 | 26.1 | 9.0 | 11.1 | 18.6 | 10.8 | 11.3 |
Osteoarthritis | 10.0 | 11.5 | 10.4 | 9.4 | 8.9 | 14.4 | 8.4 | 12.2 |
Renal Disease | 3.7 | 4.6 | 2.9 | 2.4 | 4.6 | 10.8 | 4.5 | 6.4 |
Nutritional Status | ||||||||
Malnutrition | 2.3 | 2.3 | 2.8 | 0.5 | 4.8 | 6.2 | 5.3 | 2.1 |
Obesity | 9.1 | 9.3 | 7.4 | 8.3 | 10.6 | 8.6 | 12.1 | 8.2 |
History of Other Conditions/Events Prior to Chemotherapy Course, % | ||||||||
Anemia | 20.9 | 19.9 | 18.0 | 12.4 | 36.2 | 30.9 | 41.6 | 25.9 |
Neutropenia | 2.3 | 2.3 | 1.9 | 3.0 | 1.2 | 3.3 | 1.1 | 8.6 |
Infection | 60.7 | 59.8 | 61.9 | 60.9 | 61.8 | 61.5 | 63.1 | 61.2 |
History of Chemotherapy | 4.8 | 5.0 | 3.5 | 5.1 | 3.4 | 10.7 | 2.9 | 19.0 |
History of Hospitalization for Any Reason | 45.2 | 48.4 | 46.8 | 28.3 | 65.1 | 59.4 | 77.1 | 39.3 |
History of Radiation Therapy | 16.2 | 19.0 | 44.4 | 4.1 | 21.6 | 15.1 | 13.3 | 3.9 |
Recent Surgery | 35.2 | 33.6 | 26.8 | 38.0 | 36.0 | 30.0 | 40.6 | 23.1 |
Proxies for Health Status | ||||||||
Hospice, % | 0.4 | 0.5 | 0.2 | 0.3 | 0.5 | 0.6 | 0.5 | 0.4 |
SNF, % | 1.5 | 2.2 | 1.2 | 0.6 | 1.8 | 3.7 | 1.8 | 2.1 |
Pre-Chemotherapy Expenditures ($) | ||||||||
Mean (SD) | 48,669 (47,526) | 48,179 (50,374) | 50,328 (48,500) | 40,918 (33,823) | 57,176 (53,867) | 65,571 (70,875) | 62,275 (55,302) | 47,412 (49,110) |
Proxies for Physical Function, % | ||||||||
Use of Hospital Bed | 0.5 | 0.8 | 0.5 | 0.2 | 0.6 | 1.0 | 0.6 | 0.4 |
Use of Supplemental Oxygen | 4.4 | 7.7 | 7.9 | 1.8 | 2.9 | 6.8 | 2.7 | 3.3 |
Use of Walking Aid | 2.5 | 3.3 | 2.6 | 1.4 | 2.8 | 5.0 | 2.9 | 3.1 |
Use of Wheelchair | 0.8 | 1.3 | 0.7 | 0.4 | 0.6 | 1.8 | 0.6 | 1.1 |